Lipid metabolism as a target for cancer drug resistance: progress and prospects

Zi'an Wang; Yueqin Wang; Zeyun Li; Wenhua Xue; Shousen Hu; Xiangzhen Kong

doi:10.3389/fphar.2023.1274335

Lipid metabolism as a target for cancer drug resistance: progress and prospects

Front Pharmacol. 2023 Sep 28:14:1274335. doi: 10.3389/fphar.2023.1274335. eCollection 2023.

Authors

Zi'an Wang^{1

2}, Yueqin Wang^{1

2}, Zeyun Li^{1

2}, Wenhua Xue^{1

2}, Shousen Hu³, Xiangzhen Kong^{1

2}

Affiliations

¹ Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
² Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou University, Zhengzhou, China.
³ Department of Otolaryngology Head and Neck Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Abstract

Cancer is the world's leading cause of human death today, and the treatment process of cancer is highly complex. Chemotherapy and targeted therapy are commonly used in cancer treatment, and the emergence of drug resistance is a significant problem in cancer treatment. Therefore, the mechanism of drug resistance during cancer treatment has become a hot issue in current research. A series of studies have found that lipid metabolism is closely related to cancer drug resistance. This paper details the changes of lipid metabolism in drug resistance and how lipid metabolism affects drug resistance. More importantly, most studies have reported that combination therapy may lead to changes in lipid-related metabolic pathways, which may reverse the development of cancer drug resistance and enhance or rescue the sensitivity to therapeutic drugs. This paper summarizes the progress of drug design targeting lipid metabolism in improving drug resistance, and providing new ideas and strategies for future tumor treatment. Therefore, this paper reviews the issues of combining medications with lipid metabolism and drug resistance.

Keywords: chemotherapy resistance; combination drug; drug resistance; inhibitor; lipid metabolism; targeted therapy.

Publication types

Review

Grants and funding

The authors declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by grants from the National Natural Science Foundation of China (81903094, 81600812), and the Natural Science Foundation of Henan Province (222300420566).